Reid Hoffman leaves Microsoft’s board to go ‘founder mode’ with AI drug startup Manus
What happened
Reid Hoffman is stepping down from Microsoft’s board of directors after nearly ten years. The departure was disclosed in a regulatory filing on Thursday. Hoffman joined the Microsoft board in 2016 when the company acquired LinkedIn for $26.2 billion, a business Hoffman co-founded. He is leaving to focus full time on Manus, his AI-driven drug discovery startup. Hoffman wants to enter what he calls “founder mode” to deepen the company’s push into AI-powered pharmaceutical research.
Why it matters
Hoffman’s exit signals a clear shift in priorities from corporate board oversight to hands-on startup leadership, specifically in AI for drug discovery. Manus aims to speed up and improve drug research by applying AI models to biological and chemical data, an area gaining serious interest with the promise to trim development costs and shorten timelines. Microsoft loses a high-profile tech veteran with deep AI and business experience, while Manus gains a founder fully committed to advancing AI in healthcare. For investors and operators, this signals increasing confidence that AI startups focused on drug R&D warrant heavy founder involvement to navigate scientific and regulatory complexities.
What to watch next
Manus’ progress and funding will be key indicators of this move’s payoff. Watch for partnerships or clinical trial milestones that show AI is delivering measurable improvements in drug candidate identification. Microsoft’s board composition and AI strategy may also shift as it loses direct input from Hoffman’s startup expertise. Broader biotech and AI communities should track how founder-led startups balance technical demands with market and regulatory realities. Hoffman’s transition exemplifies how leading AI entrepreneurs are moving deeper into specialized sectors rather than sitting on large tech boards.
AI Quick Briefs Editorial Desk
